Medivir announces positive topline results from phase IIa osteoarthritis study, showing disease-modifying benefit of MIV-711 on joint structure
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces positive top line data from MIV-711-201, the 6-month initial phase IIa study of MIV-711 in patients with moderate knee osteoarthritis. MIV-711, which is being developed as a disease-modifying osteoarthritis drug (DMOAD), demonstrated benefit on joint structure in the study. Patients who received MIV-711 for 6 months had significantly lower increases in bone area and cartilage thinning in the diseased knee compared to patients who received placebo. With clinical data demonstrating MIV-711’s potential to be the first